CDK4/6 Inhibition in HR+ HER2- Breast Cancer

What are the downstream signaling changes and biomarkers of CDK4/6 inhibition in HR+ HER2- breast cancer?

CDK4/6 inhibition induces cell cycle arrest through Rb pathway suppression and E2F downregulation, reduces immunosuppressive cells, and alters growth factor signaling, with key biomarkers including high ER and intact Rb for sensitivity versus IFN pathway activation, Cyclin D1/CDK4 overexpression, and PI3K/mTOR hyperactivation for resistance.

Abstract

CDK4/6 inhibition in HR+ HER2- breast cancer induces multiple downstream signaling changes beyond primary cell cycle arrest. Prevention of Rb phosphorylation leads to G1 arrest and downregulation of E2F-regulated genes including RRM2, TOPO2A, MKI67, MCM7, and CDK2, with treatment shifting tumors from high-risk luminal B to low-risk luminal A molecular phenotype. Growth factor signaling pathways show context-dependent alterations: baseline FGFR2 and ERBB3 expression associate with greater benefit from CDK4/6 inhibition, while acquired PI3K/mTOR hyperactivation drives resistance through Cyclin D1 and CDK4 overexpression. Immune signaling exhibits dual patterns, with beneficial reduction of immunosuppressive Tregs and MDSCs during treatment (p<0.0001) but aberrant IFN/STAT1 pathway activation associated with intrinsic and acquired resistance. Additional changes include suppression of ubiquitin-conjugating enzymes UBE2C, UBE2S, and UBE2T, downregulation of DNA repair pathways in resistant cells, and impairment of radiation-induced ERK and NF-κB/c-Myc signaling.

Predictive biomarkers of resistance include the IFN-related palbociclib-resistance signature (IRPS), overexpressed Cyclin D1 and CDK4 proteins, IL6/STAT3 pathway activation, and baseline Treg levels, while markers of sensitivity include high ER levels, Rb wild-type status, low cyclin E, and low p16. Despite comprehensive biomarker analysis in 666 patients, the PALOMA-2 trial found no single baseline marker predicting lack of benefit, suggesting broad initial efficacy. However, approximately 25-35% of patients demonstrate intrinsic resistance, and nearly all eventually acquire resistance through mechanisms including RB1 loss, cyclin E1 amplification, ERBB2/BRAF mutations, and PI3K/mTOR pathway activation. Strategies to overcome resistance include PI3K/mTOR inhibition to restore CDK4/6 inhibitor sensitivity and combined STAT3/PARP inhibition, with mTOR pathway activation correlating with clinical benefit to triplet therapy in CDK4/6 inhibitor-pretreated patients.

Results

Characteristics of Included Studies

The review included 10 studies investigating downstream signaling changes and biomarkers of CDK4/6 inhibition in HR+ HER2- breast cancer, comprising 3 clinical studies and 7 preclinical studies.

The studies investigated different aspects of CDK4/6 inhibition, including clinical efficacy, resistance mechanisms, downstream signaling pathways, and immune modulation. Three studies used palbociclib exclusively, one used abemaciclib, three tested multiple CDK4/6 inhibitors, and two did not specify the inhibitor. Among clinical studies, one was treatment-naive and one enrolled CDK4/6 inhibitor-pretreated patients.

Downstream Signaling Changes Following CDK4/6 Inhibition

Cell Cycle Pathway Changes

CDK4/6 inhibition consistently affected core cell cycle machinery across studies. The primary mechanism involved prevention of retinoblastoma (Rb) protein hyperphosphorylation, leading to G1 cell cycle arrest. This was accompanied by reduction in cell cycle progression markers including phospho-Rb, TOPOIIa, phosphohistone-H3, and FOXM1. Transcriptional analysis revealed downregulation of E2F-regulated genes including RRM2, TOPO2A, MKI67, MCM7, and CDK2, which tracked with growth inhibitory response.

CDK4/6 inhibition induced a molecular shift from high-risk luminal B to low-risk luminal A phenotype, with genes repressed by treatment strongly associated with clinical prognosis in ER+/HER2- cases. Importantly, treatment elicited induction of a comparable number of genes involved in multiple processes beyond cell cycle suppression, suggesting complex transcriptional rewiring.

In resistance settings, alterations in cell cycle machinery included loss-of-function alterations in RB1, high cyclin E1 mRNA expression, amplifications of AURKA, and CDK6 overexpression. Palbociclib-resistant cells exhibited overexpression of Cyclin D1 and CDK4 proteins due to upregulated protein synthesis, with silencing of these proteins leading to cell cycle arrest.

Growth Factor Signaling Alterations

Multiple growth factor signaling pathways showed altered activity following CDK4/6 inhibition. Tumors with increased expression of FGFR2 and ERBB3 mRNA demonstrated greater PFS gain from palbociclib addition, suggesting interplay between steroid hormone and peptide growth factor signaling drives CDK4/6 dependence.

In resistant cells, the PI3K/mTOR pathway exhibited hyper-activation, leading to increased phosphorylation of 4E-BP1 and higher levels of Cyclin D1 and CDK4 translation. Tumor samples after palbociclib progression showed significantly higher levels of Cyclin D1, CDK4, p-AKT, and p-4E-BP1. Genomic analysis revealed oncogenic pathways including PI3K/mTOR, FGFR, and ERBB were enriched in resistant samples, with consistency between oncogenic mutations and transcriptional signature activities in ER, PI3K/AKT/mTOR, and RTK/MAPK pathways.

CDK4/6 inhibition also reduced radiation-induced activation of ERK and NF-κB/c-Myc signaling pathways, suggesting broader effects on growth factor-activated cascades.

Immune Signaling Changes

Aberrant interferon (IFN) signaling emerged as a key resistance mechanism. High IFN signaling was associated with reduced CDK4/6 inhibitor sensitivity, with an “IFN-related palbociclib-resistance Signature” (IRPS) derived from transcriptomic analysis. PalboR derivatives displayed dramatic activation of IFN/STAT1 signaling compared to untreated counterparts. The IRPS score was significantly higher in luminal B versus luminal A subtypes and correlated with increased gene expression of immune checkpoints, endocrine resistance, and poor prognosis.

In palbociclib-resistant cells, the IL6/STAT3 pathway was induced while DNA repair and estrogen receptor pathways were downregulated. Patient samples post-palbociclib progression showed altered IL6/STAT3 signaling compared to pretreatment samples.

CDK4/6 inhibition treatment significantly downregulated circulating regulatory T cells (Tregs) and myeloid-derived suppressor cells (M-MDSCs and PMN-MDSCs) from baseline (p<0.0001 and p<0.05, respectively). The effector Treg subset (CD4+CD25+FOXP3highCD45RA-) was strongly reduced (p<0.0001). Conversely, treatment increased levels of CD4+ T cells and anti-tumor CD137+CD8+ T cells (p<0.05), suggesting relief from immunosuppression.

Lower PD-1 levels were associated with greater benefit from palbociclib plus letrozole, while the PD-1 signaling pathway was associated with reduced PFS benefit.

Ubiquitin-Proteasome Pathway Modulation

CDK4/6 inhibitors suppressed expression of three ubiquitin-conjugating enzymes: UBE2C, UBE2S, and UBE2T. Palbociclib and ribociclib decreased UBE2C at both mRNA and protein levels, though this phenomenon was not shared with abemaciclib. These E2 enzymes modulate several E3 ubiquitin ligases, including the APC/C complex which plays a role in G1/S progression.

DNA Repair and Additional Pathways

CDK4/6 inhibitors impaired the DNA-DSB repair mechanism activated by radiation. In palbociclib-resistant cells, DNA repair pathways were downregulated, and estrogen receptor pathways showed reduced activity. Patient samples post-progression demonstrated alterations in estrogen receptor, DNA repair, and IL6/STAT3 signaling compared to pretreatment.

Metabolic pathways were also affected, with increased glucose and glutamine metabolism, increased cell size, and elevated ATP levels observed following CDK4/6 inhibition. However, these metabolic changes were mitigated by concurrent endocrine therapy.

Biomarker Findings

Predictive Biomarkers of Response and Resistance

Multiple baseline markers showed associations with CDK4/6 inhibitor response. Higher CDK4 levels were associated with endocrine resistance, which was mitigated by palbociclib addition. Lower PD-1 levels at baseline associated with greater benefit from palbociclib plus letrozole.

For abemaciclib, predictive biomarkers of response included high ER levels, Rb wild-type status, high Rb total and phosphoprotein levels, lack of cyclin E amplification, low cyclin E protein, and low p16 protein levels. These markers reflected dependency on the cyclinD:CDK4/6:Rb signaling pathway.

Resistance-associated predictive biomarkers included overexpressed Cyclin D1 and CDK4 proteins, the IFN-related palbociclib-resistance Signature (IRPS), IL6/STAT3 pathway induction, and downregulation of DNA repair and estrogen receptor pathways. PI3K/AKT/mTOR mutations and high mTORC1 pathway activity correlated with clinical benefit to combined estrogen receptor, CDK4/6, and mTOR inhibition.

In the clinical trial testing triplet therapy after CDK4/6 inhibitor progression, genomic and transcriptomic features enabled identification of known or putative drivers of resistance in nearly every patient (22/23), with several patients showing transcriptomic features as sole drivers.

Prognostic Biomarkers

Higher ESR1 gene expression was associated with greater benefit from both placebo plus letrozole and palbociclib plus letrozole. Genes repressed by CDK4/6 inhibition were strongly associated with improved prognosis and reduced risk of recurrence.

The IRPS score correlated with poor prognosis in primary ER+/HER2- tumors. UBE2C/UBE2T expression levels were associated with breast cancer survival. Activating ESR1 mutations were identified in Luminal A/B subtypes while ERBB2/BRAF mutations occurred in HER2-E subtypes in mutually exclusive patterns.

Baseline Treg levels were associated with response to CDK4/6 inhibitor treatment, with Treg levels both at baseline and during treatment showing prognostic value.

Pharmacodynamic Biomarkers

CDK4 levels showed association with endocrine resistance, suggesting a role in drug activity. The pharmacodynamic biomarkers for abemaciclib included mRNA expression of RRM2, TOPO2A, MKI67, MCM7, and CDK2, which are directly regulated by E2F transcription factor downstream of Rb.

Hyper-activated PI3K/mTOR pathway markers, including p-AKT and p-4E-BP1, served as pharmacodynamic indicators. Decrease in UBE2C at mRNA and protein levels by palbociclib and ribociclib demonstrated drug activity on the ubiquitin-proteasome pathway. Activation of IFN/STAT1 signaling in resistant derivatives indicated pathway engagement.

Reduction in Tregs and MDSCs alongside increase in CD4+ and CD137+CD8+ T cells indicated immune modulation by CDK4/6 inhibitors. Impaired DNA-DSB repair mechanism and reduced ERK and NF-κB/c-Myc signaling pathways also served as pharmacodynamic markers.

Resistance Mechanisms

Intrinsic Resistance

Approximately 25-35% of patients demonstrated intrinsic resistance to CDK4/6 inhibitors. Molecular features of intrinsic resistance included high IFN signaling and the IRPS signature. High p16 protein levels and amplification of cyclin E were associated with reduced sensitivity to abemaciclib.

Baseline loss-of-function alterations in RB1, high cyclin E1 expression, low ER expression, and basal molecular subtype represented intrinsic resistance mechanisms. Higher CDK4 levels at baseline were associated with endocrine resistance, though this could be mitigated by palbociclib.

Acquired Resistance

Nearly all patients eventually acquired resistance during CDK4/6 inhibitor treatment. Acquired resistance mechanisms included activation of IFN/STAT1 signaling, dramatic upregulation compared to untreated cells. IL6/STAT3 pathway induction occurred in palbociclib-resistant cells, along with downregulation of DNA repair and estrogen receptor pathways.

Acquired genomic alterations driving resistance included activating mutations in ERBB2, BRAF, and PIK3CA, and amplifications in FGFR1 and ERBB2. Overexpression of Cyclin D1 and CDK4 proteins developed in resistant cells due to hyper-activation of the PI3K/mTOR pathway.

Dysregulation of key signaling pathways downstream of ER and/or HER2 alterations contributed to acquired resistance, particularly in metastatic settings. Aberrant mitogenic signaling pathway activation represented another acquired resistance mechanism.

Cross-Resistance Patterns

Palbociclib-resistant cells demonstrated cross-resistance to other CDK4/6 inhibitors and endocrine therapy. This included resistance to estrogen receptor downregulation. The IRPS signature correlated with increased gene expression of immune checkpoints and endocrine resistance. Patients showing resistance to CDK4/6 inhibitors also demonstrated resistance to endocrine therapy.

Strategies to Overcome Resistance

Targeting the PI3K/mTOR pathway with specific PI3Kα inhibitor (BYL719) or mTOR inhibitor (everolimus) reduced Cyclin D1 and CDK4 protein levels and restored sensitivity to palbociclib. Combined inhibition of STAT3 and PARP significantly increased cell death in palbociclib-resistant cells, suggesting this combination could effectively treat acquired resistance.

Targeting the mTOR pathway showed promise, as mTOR pathway activation correlated with clinical benefit. Selection of patients based on intact Rb pathway signaling could identify those who may benefit from abemaciclib therapy. Targeting the interplay between steroid hormone and peptide growth factor signaling was proposed to overcome resistance.

Endocrine therapy prevented compensatory growth that could contribute to resistance, and discontinuous dosing schedules may limit mitogenic signaling to prevent early resistance. Using CDK4/6 inhibitors to reduce immunosuppression and enhance checkpoint inhibitors represented another strategy.

Clinical Correlations of Molecular Findings

Response Rates and Molecular Subgroups

The PALOMA-2 trial demonstrated that palbociclib plus letrozole conferred efficacy on both luminal A and B patients, with no single biomarker or cassette of markers associated with lack of benefit from combination treatment.

In the CDK4/6 inhibitor-pretreated population, the clinical benefit rate for triplet therapy (exemestane plus everolimus plus palbociclib) was 18.8%. Among patients treated with CDK4/6 inhibitors plus aromatase inhibitors in first-line, 59% achieved complete or partial response, while in second-line with fulvestrant, 14% achieved response.

The IRPS and other IFN-related signatures were highly enriched in patients with tumors exhibiting intrinsic resistance to CDK4/6 inhibitors. Sensitivity to abemaciclib was observed predominantly in luminal ER+/HER2- and ER+/HER2+ subtypes.

Progression-Free Survival Associations

Higher CDK4 levels were associated with endocrine resistance and shorter PFS in the placebo arm, with this resistance mitigated by palbociclib. Lower PD-1 levels associated with greater PFS benefit from palbociclib plus letrozole. Active growth factor signaling, exemplified by FGFR2 and ERBB3 expression, was associated with greater PFS gain from palbociclib addition.

The IRPS score correlated with increased gene expression of immune checkpoints and poor prognosis, suggesting associations with shortened PFS. Improved PFS was associated with abemaciclib plus fulvestrant in the MONARCH-2 clinical trial.

Resistance to CDK4/6 inhibitors was associated with estrogen receptor downregulation and alterations in IL6/STAT3 and DNA damage response pathways. The hyperactivation of the PI3K/mTOR pathway in resistant cells suggested associations with shortened PFS.

CDK4/6 inhibition treatment shifted ER+/HER2- models from high-risk luminal B to low-risk luminal A molecular phenotype, associated with improved prognosis.

Immune Correlates of Response

The decrease in Treg levels was significantly greater in responder patients compared to non-responder patients. Treg levels at baseline (>T0) and Treg effector levels at T0 were significant prognostic factors, with a multivariate analysis model correctly classifying 74% of patients. The area under the ROC curve was 0.701, indicating moderate predictive accuracy for immune biomarkers.

Synthesis

The studies revealed substantial mechanistic heterogeneity in CDK4/6 inhibitor response and resistance, requiring synthesis across multiple dimensions to explain divergent findings.

Context-Dependent Mechanisms

Different resistance mechanisms dominated in distinct clinical contexts. Intrinsic resistance (25-35% of patients) was primarily characterized by baseline pathway alterations including high IFN signaling, RB1 loss, high cyclin E1, and immunosuppressive phenotypes. In contrast, acquired resistance that developed during treatment involved activation of compensatory signaling pathways not present at baseline, including IL6/STAT3 pathway induction, PI3K/mTOR hyperactivation, and ERBB2/BRAF mutations.

This temporal distinction explains why biomarker studies using baseline samples (PALOMA-2) found no single marker predicting lack of benefit, while studies examining progression samples identified multiple resistance drivers. Both observations are correct within their respective timeframes: CDK4/6 inhibitors provide broad initial benefit regardless of baseline markers, but acquired alterations subsequently drive progression.

The setting of prior CDK4/6 inhibitor exposure further modified resistance patterns. In the triplet therapy trial enrolling CDK4/6 inhibitor-pretreated patients, resistance mechanisms were identifiable in nearly all patients (22/23), with genomic drivers in RTK/MAPK, PI3K/AKT/mTOR pathways prevalent. The modest 18.8% clinical benefit rate in this pretreated population contrasted with the broad efficacy in treatment-naive patients, consistent with accumulated resistance alterations limiting subsequent treatment options.

Integration of Transcriptomic and Genomic Features

Studies employing both genomic and transcriptomic analyses revealed that genomic resistance mechanisms associated with corresponding transcriptomic signatures. ESR1 mutations linked with high estrogen receptor pathway activity in Luminal A/B subtypes, while ERBB2/BRAF mutations associated with high RTK/MAPK pathway activity in HER2-E subtypes. This concordance validated transcriptomics as complementary to genomics, with transcriptomic features identifying pathway drivers even absent genomic alterations.

The molecular shift from luminal B to luminal A phenotype following CDK4/6 inhibition provided mechanistic insight into clinical benefit. Genes repressed by CDK4/6 inhibition strongly associated with poor prognosis, explaining why their suppression improved outcomes. However, induced genes also associated with improved outcomes, suggesting dual beneficial effects beyond simple cell cycle arrest. The induction of growth-promoting pathways that could contribute to resistance was antagonized by concurrent endocrine therapy, explaining the superior efficacy of combination versus monotherapy.

Pathway Crosstalk and Therapeutic Implications

Growth factor and hormone signaling exhibited complex interdependence. Tumors with active FGFR2/ERBB3 signaling showed greater CDK4/6 inhibitor benefit, suggesting growth factor pathway activation increased CDK4/6 dependence rather than conferring resistance. Conversely, PI3K/mTOR hyperactivation in resistant cells drove Cyclin D1/CDK4 overexpression, creating CDK4/6 inhibitor insensitivity through target protein excess. This distinction explained why PI3K/mTOR pathway markers showed opposing relationships with benefit depending on context: moderate baseline activity associated with CDK4/6 inhibitor sensitivity, while acquired hyperactivation drove resistance.

The differential effects of palbociclib, ribociclib, and abemaciclib on UBE2C expression indicated mechanistic distinctions between CDK4/6 inhibitors despite shared primary targets. This heterogeneity may contribute to non-cross-resistance and sequential efficacy, though clinical validation remains limited.

Immune Modulation as Dual Mechanism

CDK4/6 inhibition’s immune effects showed apparent contradictions: treatment reduced immunosuppressive Tregs and MDSCs with benefit correlating with immune activation, yet high baseline IFN signaling associated with resistance. This paradox resolves through mechanistic separation: CDK4/6 inhibitors beneficially reduced regulatory immune populations suppressing anti-tumor immunity, while aberrant chronic IFN pathway activation represented a resistance mechanism independent of CDK4/6 inhibitor-induced immune changes. The IRPS signature’s enrichment in luminal B versus luminal A tumors and correlation with poor prognosis indicated this represented a tumor-intrinsic resistance mechanism rather than response to treatment.

Methodological Heterogeneity and Quality Weighting

Preclinical studies (7/10 sources) provided detailed mechanistic insights into signaling changes and resistance pathways but used cell lines and xenografts that may not fully recapitulate clinical heterogeneity. The phase III PALOMA-2 trial with 666 patients represented the highest-quality evidence for baseline biomarker associations, finding remarkably consistent benefit across subgroups. However, its baseline-only design limited detection of acquired resistance mechanisms identified in studies with serial sampling.

The phase I/II triplet therapy trial employed comprehensive genomic and transcriptomic profiling at progression, providing high-quality evidence for acquired resistance mechanisms despite modest sample size (32 patients). The prospective observational study with 50 patients contributed unique evidence on immune dynamics through serial blood sampling, though lacked genomic correlates. Studies with abstract-only availability provided valuable mechanistic hypotheses requiring validation.

Resistance mechanisms with convergent evidence across clinical and preclinical studies merit greatest confidence: PI3K/mTOR pathway activation was identified in both palbociclib-resistant cell lines and patient tumor samples, with clinical correlation to treatment benefit when targeted. Similarly, immune checkpoint activation was observed in both IFN-high cell lines and patient samples. Mechanisms identified solely in preclinical models (e.g., UBE2C suppression) require clinical validation.

References

1. R. Finn, Yuan Liu, Zhou Zhu, Miguel Martín, H. Rugo, and 8 more (2019) Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer. Clinical Cancer Research
2. E. Knudsen, A. Witkiewicz (2016) Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer. OncoTarget
3. F. Scirocchi, S. Scagnoli, A. Botticelli, A. Di Filippo, C. Napoletano, and 7 more (2022) Immune effects of CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: Relief from immunosuppression is associated with clinical response. EBioMedicine
4. Wen-Chi Yang, M. Wei, Yi-Hsuan Lee, Chiun-Sheng Huang, S. Kuo (2024) Radiosensitizing effects of CDK4/6 inhibitors in hormone receptor-positive and HER2-negative breast cancer mediated downregulation of DNA repair mechanism and NF-κB-signaling pathway. Translational Oncology
5. Carmine De Angelis, Xiaoyong Fu, M. Cataldo, A. Nardone, Resel Pereira, and 25 more (2021) Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clinical Cancer Research
6. Neil A. O’Brien, D. Conklin, R. Beckmann, Tong Luo, Kevin Chau, and 8 more (2018) Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer. Molecular Cancer Therapeutics
7. Zijie Cai, Jingru Wang, Yudong Li, Qianfeng Shi, Liang Jin, and 12 more (2022) Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors. Science China Life Sciences
8. Chih-Yi Lin, Chung-Jen Yu, Chun-Yu Liu, T. Chao, Chi-Cheng Huang, and 2 more (2022) CDK4/6 inhibitors downregulate the ubiquitin-conjugating enzymes UBE2C/S/T involved in the ubiquitin–proteasome pathway in ER + breast cancer. Clinical and Translational Oncology
9. N. Kettner, S. Vijayaraghavan, M. Durak, Tuyen N Bui, Mehrnoosh Kohansal, and 17 more (2019) Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer. Clinical Cancer Research
10. J. G. T. Zañudo, R. Barroso-Sousa, Esha Jain, Qing Jin, Tianyu Li, and 14 more (2022) Genomic and Transcriptomic Determinants of Resistance to CDK4/6 Inhibitors and Response to Combined Exemestane plus Everolimus and Palbociclib in Patients with Metastatic Hormone Receptor Positive Breast Cancer. medRxiv